Martín Lázaro

José Antonio Marina, filósofo: «La felicidad es satisfacer tres necesidades: el bienestar personal ... theobjective.com/lifestyle/2026…

Real-world study of apalutamide and enzalutamide in metastatic hormone-sensitive #ProstateCancer. @bilenma @EmoryUniversity joins @neerajaiims @huntsmancancer to discuss this analysis which followed FDA guidance for real-world evidence, requiring pre-planned protocols with defined study design, endpoints, and statistical methodology before data analysis. #WatchNow on UroToday > bit.ly/43iLvOp

UC Takeaways from #ASCOGU26 1) KEYNOTE-B15 is a landmark. Periop EV+pembro vs gem/cis in cis-eligible MIBC: EFS HR 0.53, pCR 55.8% vs 32.5%, OS benefit. First regimen to displace cisplatin in curative-intent bladder cancer in ~25 yrs.

What REALLY makes a good oncologist? in @JCO_ASCO After 10 years and 203 JCO essays, one thing became clear: expertise alone isn’t enough. Patient-centered care. Clear, authentic communication. Emotional intelligence. And the harder work Showing up again and again. Openness

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors in @ESMO_Open. Evidence-based consensus statements providing guidance on the safety of combining RT with EGFR, ALK, or BRAF/MEK inhibitors. esmoopen.com/article/S2059-…

Agree with @Uromigos @tompowles1 about @rohitjainMD huge effort to get this pilot trial done, showing feasibility, manageable toxicity & impressive efficacy signal with EV/erda in pretreated mUC. Interested to see FORAGER-2 in 1L setting #GU26 @OncoAlert @FaltasLab @DrScottTagawa x.com/uromigos/statu…

IMVIGOR011: ctDNA guided adjuvant atezolizumab in MIBC shows a ctDNA risk adapted approach identified high risk patients who benefit from ICI therapy, sparing persistently ctDNA-ves (at much lower risk) toxicity. Here #GU26 we show ctDNA+ves have dynamic MTM levels (a bit like

Disitimab Vedotin (HER2/MMAE ADC) was tested in HER2-positive (n=73, RR 55%) and HER2-low (n=78, RR 53%) pretreated advanced bladder cancer outside of China. No clear efficacy difference according to HER status(PFS 6 months and OS 17-20 mnths). Only about 20% of UC patients are

ASCO GU 2026 – Top 15 Trials with Potential Practice Impact @ASCO #GU26

RT @tactics_md: Damos la bienvenida al #OncoPrecision26 con la apertura institucional y científica del simposio. Vigo se convierte en pun…

OncoAlert🚨The #AUC3 WEEK 2026 Their Publication is NOW OUTARTICLE HERE: 👉 buff.ly/bAgkPQC Presenter Dr. Brian Rini 🇺🇸 (Adjuvant Therapy Debate) CON in #KidneyCancer RCC Conclusions There are relevant data points on both sides of the benefit:risk equation to consider

FORMULA-509 @EUplatinum 2026 pubmed.ncbi.nlm.nih.gov/41672869/ Can we safely intensify short-course ADT during salvage RT after prostatectomy? @DrPaulNguyen @DrRanaMcKay 345 pts, sRT + 6 mo GnRH agonist ▪️ Bicalutamide ▪️ vs Abiraterone + Prednisone + Apalutamide 🎯 Overall population

Última oportunidad para sumarte a #OncoPrecision26 📍 Vigo · 19–20 feb 2026 La #OncologíadePrecisión ya forma parte de la práctica clínica: NGS, IA, nuevas dianas terapéuticas y aplicación real en consulta, de la mano de especialistas de referencia a nivel nacional. ‼️👇 Mañana se cierran INSCRIPCIONES: tacticsmd.net/actividad/viii… @OncoHULA @mlazqui @SOG_Galicia

Millones de visitantes, vecinos hartos y Vigo contra Badalona: ¿cómo llegaron a esto las luces de Navidad? elpais.com/icon/2025-12-1…

Leído en ⁦@applesfera⁩ : “He viajado a Viena sin hablar alemán confiando solo en la traducción de los AirPods: sorprende, pero no es perfecta” applesfera.com/airpods/he-via…

Tissue and peripheral T cell receptor repertoire predicts immunotherapy response and progression-free survival in NSCLC patients nature.com/articles/s4159…

Los algoritmos adivinan cómo somos o cuánto ganamos solo con analizar nuestra foto theconversation.com/los-algoritmos…

Me hace mucha ilusión compartir que somos finalistas en #INNOVAH2025 🙌 Con Código Rojo queremos transformar la forma en la que los médicos acceden a conocimiento y formación, usando #IA como aliada ¿Nos echas una mano con un ❤️ y un RT? @NovartisSpain @SETH__Oficial @sehh_es

Seis cosas que los médicos de urgencias desearían que evitaras nytimes.com/es/2025/09/06/…

Real-world data on avelumab in first-line maintenance therapy for advanced or metastatic urothelial carcinoma: the SOGUG-AVELUMAB RWD study | Clinical and Translational Oncology link.springer.com/article/10.100…